@misc{10481/75680,
year = {2022},
month = {6},
url = {http://hdl.handle.net/10481/75680},
abstract = {Background: Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer.
However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers.
Liquid biopsy is the non-invasive and repeatable analysis of biological material in body fluids and a promising
tool for cancer biomarkers discovery. In particular, there is growing evidence that extracellular vesicles (EVs) play
an important role in tumor progression and in tumor-immune interactions. Thus, we evaluated whether extracellular
vesicle PD-L1 expression could be used as a biomarker for prediction of durable treatment response and survival in
patients with non-small cell lung cancer (NSCLC) undergoing treatment with ICIs.
Methods: Dynamic changes in EV PD-L1 were analyzed in plasma samples collected before and at 9 ± 1 weeks during
treatment in a retrospective and a prospective independent cohorts of 33 and 39 patients, respectively.
Results: As a result, an increase in EV PD-L1 was observed in non-responders in comparison to responders and was
an independent biomarker for shorter progression-free survival and overall survival. To the contrary, tissue PD-L1
expression, the commonly used biomarker, was not predictive neither for durable response nor survival.
Conclusion: These findings indicate that EV PD-L1 dynamics could be used to stratify patients with advanced NSCLC
who would experience durable benefit from ICIs.},
organization = {Center for Thoracic Oncology Icahn School of Medicine at Mount Sinai},
organization = {Borsa Dottorati FSE XXXII ciclo Unime},
organization = {United States Department of Health & Human Services},
organization = {National Institutes of Health (NIH) - USA},
organization = {NIH National Cancer Institute (NCI)	P30CA016672},
organization = {University of Pittsburgh Hillman Cancer Center},
organization = {Hillman Cancer Center's NCI Cancer Center Support Grant (CCSG)	P30CA047904},
organization = {A.S.S.O. (Associazione Siciliana Sostegno Oncologico) Onlus},
organization = {National Cancer Institute-Cancer Center Support Grant (CCSG)	P30CA134274},
organization = {Merck & Company},
publisher = {BMC},
keywords = {Extracellular vesicles},
keywords = {PD-L1},
keywords = {Biomarkers},
keywords = {Immunotherapy},
keywords = {NSCLC},
title = {Extracellular vesicle PD‑L1 dynamics predict durable response to immune‑checkpoint inhibitors and survival in patients with non‑small cell lung cancer},
doi = {10.1186/s13046-022-02379-1},
author = {De Miguel Pérez, Diego and Serrano Fernández, María José},
}